UK pharmaceutical company, Shire, is to purchase US firm NPS Pharmaceuticals in a deal worth approximately $5.2bn.
Shire is to acquire all outstanding shares of NPS Pharma for $46 per share in cash, with the firm planning to accelerate the growth of NPS Pharma’s innovative portfolio. The transaction has been approved unanimously by the Boards of Directors of both Shire and NPS Pharma. NPS Pharma is a rare disease-focused biopharmaceutical company and…
This content is for subscribers only. Subscribe now for free to read the full article.
Already a subscriber? Login